Waypoint Bio 🇺🇸
Existing Hummingbird portfolio company; the fund took part in its $20M Series A.
About Waypoint Bio
Waypoint Bio specializes in developing advanced cell therapies for solid tumors, utilizing proprietary technologies such as in silico library creation, pooled high-throughput labeling, and spatial biology profiling. Their approach incorporates AI and machine learning to optimize therapy designs, enabling the testing of thousands of potential therapies in a single experiment while facilitating rigorous analysis and rapid iteration.
Waypoint Bio is a US-based company founded in 2021, now around 20 people. It has raised $20M in disclosed funding. FundFinder classes it as Health & Bio.
Founded by Xinchen Wang (Co-founder and CEO; Massachusetts Institute of Technology), David Phizicky (Co-founder and CSO; previously Biomedical Innovation, Tsai Center for Innovative Thinking at Yale (Tsai CITY); Massachusetts Institute of Technology).
Its investors also appear on FundFinder's most-active lists for Series A · Fintech (84 funds), Series A · B2B (80 funds), Series A · Generalist (64 funds).
Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.
Series A · $20M · May 2026
Hummingbird Ventures- Hummingbird Ventures — Hummingbird Ventures was founded in Antwerp and is now based in London. · cheques £500k – £10M